Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rice University
Headquarters: Houston, TX, United States of America
Website: http://www.rice.edu
Year Founded: 1912
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 8, 2024
Finance
Neurogene draws $200M PIPE ahead of next week’s Rett syndrome data
In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week
BioCentury | Oct 25, 2024
Finance
Why Rice is launching a venture studio in Houston’s emerging biotech ecosystem
Founders see chance to build start-ups from university IP, with clinical infrastructure already in place from local institutions
BioCentury | Sep 30, 2023
Finance
Sept. 29 Quick Takes: Adlai Nortye sinks after NASDAQ listing
Plus: NASH play Madrigal raises $500M, and updates from Regeneron, Thymmune, Harvard Medical School and more
BioCentury | Sep 15, 2023
Discovery & Translation
Mini Cas protein iterations; plus Moderna’s Lassa virus vaccine and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 28, 2022
Discovery & Translation
Emerald co-founders describe in-home gait sensor to assess Parkinson’s severity and more
BioCentury’s roundup of translational news
BioCentury | Mar 5, 2022
Discovery & Translation
Three ways to selectively kill cancer cells; plus Aevis and more
BioCentury’s roundup of translational news
BioCentury | Feb 19, 2021
Translation in Brief
mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more
BioCentury’s roundup of translational news
BioCentury | Oct 21, 2020
Deals
Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials
Flexible investment model could include equity, milestones or royalties
Items per page:
1 - 10 of 41